[go: up one dir, main page]

ATE321538T1 - Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole - Google Patents

Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole

Info

Publication number
ATE321538T1
ATE321538T1 AT99941537T AT99941537T ATE321538T1 AT E321538 T1 ATE321538 T1 AT E321538T1 AT 99941537 T AT99941537 T AT 99941537T AT 99941537 T AT99941537 T AT 99941537T AT E321538 T1 ATE321538 T1 AT E321538T1
Authority
AT
Austria
Prior art keywords
ylmethylsulfinyl
benzimidazole
pyridine
oral pharmaceutical
pharmaceutical form
Prior art date
Application number
AT99941537T
Other languages
English (en)
Inventor
Rango Dietrich
Hartmut Ney
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE321538(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of ATE321538T1 publication Critical patent/ATE321538T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99941537T 1998-08-12 1999-08-07 Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole ATE321538T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98115141 1998-08-12

Publications (1)

Publication Number Publication Date
ATE321538T1 true ATE321538T1 (de) 2006-04-15

Family

ID=8232445

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99941537T ATE321538T1 (de) 1998-08-12 1999-08-07 Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole

Country Status (12)

Country Link
US (3) US7041313B1 (de)
EP (1) EP1105105B1 (de)
JP (1) JP4988088B2 (de)
AT (1) ATE321538T1 (de)
AU (2) AU772726B2 (de)
CA (2) CA2340054C (de)
DE (1) DE69930648T2 (de)
DK (1) DK1105105T3 (de)
ES (1) ES2262335T3 (de)
PT (1) PT1105105E (de)
SI (1) SI1105105T1 (de)
WO (1) WO2000009092A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US20020019642A1 (en) 1996-07-23 2002-02-14 Keith Milliman Anastomosis instrument and method for performing same
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
ES2295220T3 (es) * 2000-10-18 2008-04-16 Tyco Healthcare Group Lp Instrumento para anastomosis.
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US7241302B2 (en) 2001-10-18 2007-07-10 Tyco Healthcare Group Lp Anastomosis instrument and method for performing same
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US7195142B2 (en) 2003-05-30 2007-03-27 Tyco Healthcare Group Lp End-to-end anastomosis instrument and method for performing same
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP2004231520A (ja) * 2003-01-28 2004-08-19 Nichiko Pharmaceutical Co Ltd 保存安定性及び溶出速度に優れた医薬組成物
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
WO2017125912A1 (en) 2016-01-21 2017-07-27 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
JPS61100526A (ja) * 1984-10-22 1986-05-19 Kyowa Hakko Kogyo Co Ltd 持続性ドパミン経黒剤
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPS6339814A (ja) * 1986-08-01 1988-02-20 Teisan Seiyaku Kk トラニラストの経口用持続性製剤
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
JP2602518B2 (ja) 1988-01-27 1997-04-23 エーザイ株式会社 被覆された胃酸分泌抑制剤含有組成物
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
ATE110069T1 (de) 1989-11-29 1994-09-15 Toa Eiyo Ltd Cycloheptenopyridinderivate, verfahren zu ihrer herstellung und diese enthaltende antiulkusmitteln.
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994002140A1 (en) 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
JPH0710758A (ja) * 1993-06-22 1995-01-13 Nippon Iyakuhin Kogyo Kk 持続性セファクロル製剤
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
DE69631981T2 (de) 1995-09-21 2005-04-14 Pharma Pass Ii Llc, Irvine Lansoprazolhaltige Arzneizusammensetzung und Herstellungsverfahren
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US6749867B2 (en) * 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts

Also Published As

Publication number Publication date
JP4988088B2 (ja) 2012-08-01
EP1105105B1 (de) 2006-03-29
AU5511499A (en) 2000-03-06
CA2507743A1 (en) 2000-02-24
AU772726B2 (en) 2004-05-06
JP2002522472A (ja) 2002-07-23
CA2507743C (en) 2008-03-18
US20080226712A1 (en) 2008-09-18
AU2004202162A1 (en) 2004-06-17
WO2000009092A1 (en) 2000-02-24
AU2004202162B2 (en) 2007-03-08
DE69930648D1 (de) 2006-05-18
CA2340054A1 (en) 2000-02-24
US20060263426A1 (en) 2006-11-23
DE69930648T2 (de) 2006-12-21
US7402321B2 (en) 2008-07-22
PT1105105E (pt) 2006-07-31
US8465767B2 (en) 2013-06-18
ES2262335T3 (es) 2006-11-16
EP1105105A1 (de) 2001-06-13
CA2340054C (en) 2005-10-18
DK1105105T3 (da) 2006-07-17
US7041313B1 (en) 2006-05-09
SI1105105T1 (sl) 2006-08-31

Similar Documents

Publication Publication Date Title
ATE321538T1 (de) Orale darreichungsform für pyridin-2- ylmethylsulfinyl-1h-benzimidazole
AR034691A1 (es) Composiciones farmaceuticas de administracion oral, que contiene un inhibidor de lipasa gastrointestinal, el comprimido masticable y la galleta que los comprende
PT1109812E (pt) Pirrolobenzodiazepinas
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DE60142891D1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
TR199901077A2 (en) �spen�iyari form�lasyonlar.
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
ITRM920361A1 (it) Composizioni farmaceutiche contenenti un composto allilamminico quale principio attivo.
BR0015188A (pt) Composições farmacêuticas
DE69830504D1 (de) Antithrombotische mitteln
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
NO306654B1 (no) Farmasöytisk preparat inneholdende diklormetylenbisfosfonsyre eller salt derav for oral tilförsel
DE60205870D1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
BR0212386A (pt) Composto, formulação farmacêutica, e, uso de um composto
DE59907481D1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
DK1121127T3 (da) Orale farmaceutiske sammensætninger, som indeholder buprenorphin
SE9700885D0 (sv) New pharmaceutical formulation
DE60128100D1 (de) Analgetisches arzneimittel
EP0816366A4 (de) Imidazothiazolverbindungen
YU48915B (sh) Sulfonilkarbamid i postupak za njegovo dobijanje
TR200001121T2 (tr) Antiromatizmal madde.
DK0469440T3 (da) Faste orale applikationsformer, der som aktivt stof indeholder ifosamid
DE69635775D1 (de) Medikament gegen pulmonale herzprobleme
ES2170168T3 (es) Composiciones recubiertas entericamente de derivados de 1,5-benzodiacepina con actividad antagonista o agonista de cck.
DE60108860D1 (de) Orale zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1105105

Country of ref document: EP

EEFA Change of the company name